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James McCracken, MD, Matthew State, MD, PhD, and the American Academy of Child
and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI)Autism spectrum disorder is characterized by patterns of delay and deviance in the develop-
ment of social, communicative, and cognitive skills that arise in the ﬁrst years of life. Although
frequently associated with intellectual disability, this condition is distinctive in its course,
impact, and treatment. Autism spectrum disorder has a wide range of syndrome expression
and its management presents particular challenges for clinicians. Individuals with an autism
spectrum disorder can present for clinical care at any point in development. The multiple
developmental and behavioral problems associated with this condition necessitate multidisci-
plinary care, coordination of services, and advocacy for individuals and their families. Early,
sustained intervention and the use of multiple treatment modalities are indicated. J. Am. Acad.
Child Adolesc. Psychiatry, 2014;53(2):237–257. Key Words: autism, Practice Parameters,
guidelines, developmental disorders, pervasive developmental disordersince the ﬁrst Practice Parameter for the
Assessment and Treatment of Children,S Adolescents, and Adults with Autism
and Other Pervasive Developmental Disorders1
was published, several thousand research and
clinical articles have appeared and the diag-
nostic criteria for autism have changed. This
Parameter revision provides the opportunity to
update the previous version and incorporate
new research. Because the extant body of
research was performed under the DSM-IV-TR
diagnostic schema, the evidence will be pre-
sented using that terminology. This Parameter
is applicable to evaluation of children and ad-
olescents (17 years of age) but often will have
some relevance to adults. This document pre-
sumes basic familiarity with aspects of normal
child development and child psychiatric diag-
nosis and treatment. Unless otherwise noted,
the term child refers to adolescents and
younger children, and parents refers to theThis article can be used to obtain continuing medical education
(CME) at www.jaacap.org.
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whether they are the biological or adoptive
parents or legal guardians.
METHODOLOGY
The ﬁrst version of this Parameter was published
in 1999. For this revision, the literature search
covered the period from 1991 to March 19, 2013
using the PubMed, PsycINFO, Cochrane, and
CINAHL (EBSCO) databases. The initial searches
were inclusive and sensitive. Search terms were a
combination of MeSH headings and keywords,
and the MeSH headings were adjusted to terms
used by PsycINFO and CINAHL by using their
thesauri.
In PubMed the MeSH terms autistic disorder,
childhood development disorders—pervasive, Asperger*,
and Rett* and the keyword autism were searched.
The initial search yielded 20,807 results. Then, the
results were limited to English, human, all child
(0 to 18 years), and 1991 to March 19, 2013. Addi-
tional limits included classic article, clinical trial,
comparative study, controlled clinical trial, eva-
luation studies, guideline, historical article, meta-
analysis, practice guideline, multicenter study,
randomized controlled trial, review, twin study,Y
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yielded 3,613 articles.
In the PsycINFO database subject headings
(focused) of autism, autistic thinking, pervasive
developmental disorders, retts syndrome, aspergers,
and keyword autism were searched. The initial
search returned 24,875 articles and was then
limited to English, childhood: birth to age 12yrs,
adolescence: age 13-17 yrs, peer reviewed journal, and
1991 to March 19, 2013. The reﬁned PsycINFO
search yielded 9,583 articles.
In the Cochrane Database of Systematic Re-
views, keywords of autism, autistic, rett*, asperger*,
or (pervasive and disorder* and develop*) were
searched without additional limits. The Cochrane
search yielded 95 articles. An additional 517 ar-
ticles were retrieved from the CINAHL database,
after excluding Medline articles, by searching
autistic disorder, autism, asperger syndrome, child
development disorders, pervasive, and rett syndrome.
A total of 13,808 articles were identiﬁed and
exported to the EndNote reference management
program. After removing duplicate references,
the resulting yield from the comprehensive
search was 9,581 articles.
The titles and abstracts of all articles were
reviewed. Studies were selected for full text
review based on their place in the hierarchy of
evidence (e.g., randomized controlled trials),
quality of individual studies, and generalizability
to clinical practice. The search was augmented by
review of articles nominated by expert reviewers
and further search of article reference lists and
relevant textbook chapters. A total of 186 articles
were selected for full text examination.
CLINICAL PRESENTATION AND COURSE
Autism was ﬁrst described in 1943 by Kanner2
who reported on 11 children with an apparently
congenital inability to relate to other people but
who were quite sensitive to change in the
nonsocial environment. Kanner emphasized that
the lack of interest in people was in stark contrast
to the profound social interest of normal infants.
He also observed that when language devel-
oped at all, it was marked by echolalia, pronoun
reversal, and concreteness. The children also
exhibited unusual, repetitive, and apparently
purposeless activities (stereotypies). Autism was
initially believed to be a form of childhood psy-
chosis, but, by the 1970s, various lines of evidence
made it clear that autism was highly distinctive.
By 1980, autism was ofﬁcially recognized as a
diagnosis in DSM-III.3JOURN
238 www.jaacap.orgUnder DSM-IV-TR, the diagnosis of autism
required disturbances in each of 3 domains: social
relatedness, communication/play, and restricted
interests and activities with onset by 3 years of
age.4 The disturbance in social relatedness is
striking and includes marked impairment in
nonverbal communication, peer relationships,
and social-emotional reciprocity. Impairments in
communication include a delay or total lack of
spoken language (without an attempt to
compensate through other means) or, for verbal
individuals, a marked difﬁculty in the ability to
sustain or initiate conversation, stereotyped and
repetitive (or idiosyncratic) language, and lack of
developmentally appropriate make-believe or
social play. Impairment in interests and activities
includes encompassing preoccupations, adher-
ence to apparently nonfunctional routines or rit-
uals, stereotypies and motor mannerisms, and
persistent preoccupation with parts of objects.
There is variability in the age at which children
may present the features essential for this diag-
nosis.5 Preschool children with autism typically
present with marked lack of interest in others,
failures in empathy, absent or severely delayed
speech and communication, marked resistance to
change, restricted interests, and stereotyped
movements. Common parental concerns include
a child’s lack of language, inconsistencies in
responsiveness, or concern that the child might be
deaf. In children with autism, social and commu-
nication skills usually increase by school age;
however, problems dealing with change and
transitions and various self-stimulatory behaviors
(sometimes including self-injury) also may become
more prominent during this time.6 In adolescence,
a small number of individuals with autism make
marked developmental gains; another subgroup
will behaviorally deteriorate (e.g., tantrums, self-
injury, or aggression). Children and adolescents
with autism have an increased risk for accidental
death (e.g., drowning).7 Predictors of ultimate
outcome include the presence of communicative
speech by 5 years of age and overall cognitive
ability (IQ). Evidence that earlier detection
and provision of services improves long-term
prognosis makes early diagnosis particularly
important.8
The DSM-IV-TR category of pervasive devel-
opmental disorders included autistic disorder,
Rett’s disorder, Asperger’s disorder, childhood
disintegrative disorder, and pervasive develop-
mental disorder not otherwise speciﬁed (PDD-
NOS). Rett’s disorder was described by AndreasAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
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washing/wringing stereotyped mannerisms. In
most cases, Rett’s disorder is caused by mutations
in the gene MeCP2 (methyl-CpG-binding protein
2).9 Head circumference and development are
normal at birth and during infancy. Before 4 years
of age, head growth decelerates, purposeful hand
movements are lost, and characteristic stereo-
typed hand movements (wringing or washing)
develop.10 The central role ofMeCP2mutations in
this disorder makes it clear that boys may carry
the same mutations that lead to the full syndrome
in girls, but with differing clinical manifestations
ranging from fatal encephalopathy11 to progres-
sive but nonfatal developmental disorder12 to
nonspeciﬁc X-linked intellectual disability.13
Childhood disintegrative disorder (CDD) was
ﬁrst described by Theodor Heller in 1908.14 This
condition is characterized by a period of at least 2
years of normal development, followed by a
marked deterioration and clinically signiﬁcant loss
of at least 2 skills in the areas of receptive or
expressive language, social skills, toileting skills,
play, or motor skills.14 The onset of CDD is highly
distinctive, typically occurring at 3 to 4 years of
age and can be gradual or abrupt. Sometimes
parents report that the child experienced a period
of anxiety or dysphoria before onset of CDD
symptoms. Once established, CDD resembles
autism in clinical features,14 but the outcome is
poor. The child typically becomes mute or, at best,
regains limited speech.
Asperger’s disorder was described in 1944 but
not ofﬁcially recognized until DSM-IV. Unlike
children with autism, individuals with Asper-
ger’s disorder do not present with delays in lan-
guage acquisition or with unusual behaviors and
environmental responsiveness during the ﬁrst
years of life. Consequently, parents often have no
concerns about their child’s early development.15
Asperger originally described children who were
precocious in learning to talk but who then talked
in a formal, pedantic, 1-sided way, often about a
topic of circumscribed interest.16 Social difﬁ-
culties arise due to this idiosyncratic, 1-sided so-
cial style. The outcome in Asperger’s disorder
generally appears to be better than that for
autism, although this may, in part, relate to
better cognitive and/or verbal abilities.8,15
The term pervasive developmental disorder
not otherwise speciﬁed (PPD NOS) (also some-
times termed atypical PDD or atypical autism)
encompasses subthreshold cases on the autism
spectrum, e.g., cases in which full criteria for oneJOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATR
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the child has problems in social interaction and
some difﬁculties in communication or restricted
patterns of behavior. Although studies are
limited, individuals with PDD-NOS typically
have been characterized as less impaired, having
fewer repetitive behaviors, and having a better
prognosis than persons with autism.16
DSM-IV-TR to DSM-5
Because there was little evidence to support reli-
able and replicable diagnostic differences among
the various DSM-IV-TR PDDs,17 the DSM-5
workgroup on neurodevelopmental disorders
subsumed the prior categories under the new
diagnosis of autism spectrum disorder (ASD) in
the DSM-5. Diagnostic domains were reduced
from 3 to 2, focusing on social communication
and interaction deﬁcits and restricted, repetitive
patterns of behaviors and interests. The strict
requirement for onset before 3 years of age was
changed to onset in the early developmental
period, the occurrence of potential sensory ab-
normalities was incorporated, and a severity scale
for impairments in each of the 2 core domains
was included. Diagnostic reporting now includes
speciﬁers that may enhance descriptive subtyp-
ing of the population, including speciﬁers for the
presence or absence of intellectual impairment,
language impairment, catatonia, and known
medical, genetic, or environmental factors. The
new criteria allow for a history of symptoms that
may not be present currently, recognizing that
through intervention or normal development
some children with autism no longer present
some symptoms later in life. It will be some years
before the implications of these changes for
autism prevalence and other facets of assessment
and treatment can be fully assessed.
EPIDEMIOLOGY
Many studies, mostly conducted outside the
United States, have examined the prevalence of
autism or, less commonly, ASD or PDDs.17 Of the
approximately 36 surveys of autism available,
prevalence estimates for autistic disorder range
from 0.7 in 10,000 to 72.6 in 10,000.18 The vari-
ability in estimates reﬂects different factors,
including changes in deﬁnition. When the 18 sur-
veys conducted since the introduction of the
DSM-IV criteria are considered, estimates ranging
from 10 in 10,000 to 16 in 10,000, with a median
prevalence of 13 in 10,000, are obtained.18 The
most recent study by the Centers for DiseaseY
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of ASD in the United States as 11.3 in 1,000.19
Contrary to popular perception, data from 7 sur-
veys suggest that rates of Asperger’s disorder are
in fact lower than for typical autism (2.6 in 10,000
or one ﬁfth as common as typical autism).18
Recent observations of higher rates of autism
have led to concern that the prevalence of this dis-
order may be increasing. Various factors may
contribute to an apparent increase,20 such as dif-
ferences in diagnostic criteria and diagnostic prac-
tices, the age of children screened, and the location
of the study (see Fombonne18 for discussion).
Autism is approximately 4 times more com-
mon in males than in females, but females with
autism tend to have more severe intellectual
disability. Although the original report by Kan-
ner2 suggested a predominance of autism in more
educated families, subsequent work has not
shown this. Current approaches to the diagnosis
of ASD appear to work well internationally and
cross-culturally,3 although cultural aspects of the
condition have not received much attention.21
Within the United States, there may be underdi-
agnosis in some circumstances (e.g., in disad-
vantaged inner-city children).22ETIOLOGY
Neurobiology
Electroencephalographic (EEG) abnormalities and
seizure disorders are observed in as many as 20%
to 25% of individualswith autism.23 The high rates
of epilepsy suggest a role for neurobiologic factors
in autism.13,24,25 The number of areas affected
by autism suggests that a diverse and widely
distributed set of neural systems must be affected.
Although various theories have posited potential
loci for difﬁculties, deﬁnitive data are lacking.
Postmortem studies have shown various abnor-
malities, particularly within the limbic system.25
Functional magnetic resonance imaging proce-
dures have identiﬁed difﬁculties in tasks in-
volving social and affective judgments and
differences in the processing of facial and non-
facial stimuli.26 Structural magnetic resonance
imaging has shown an overall brain size increase
in autism, and diffusion tensor imaging studies
have suggested aberrations in white matter tract
development.27 One of the most frequently repli-
cated neurochemical ﬁndings has been the eleva-
tion of peripheral levels of the neurotransmitter
serotonin. The signiﬁcance of this ﬁnding remains
unclear. A role for dopamine is suggested givenJOURN
240 www.jaacap.orgthe problems with overactivity and stereotyped
mannerisms and the positive response of such
behaviors to neuroleptic medications.28
During the past decade, much concern has
focused on vaccines as a possible postnatal
environmental cause for ASD, with the concern
focused on the possibility that the measles-
mumps-rubella vaccine may cause autism or
that thimerosal (a mercury-containing preserva-
tive now removed from all single-dose vaccines)
might do so.29 The preponderance of available
data has not supported either hypothesis (see
Rutter30 for a review). However, a possible role of
the immune system in some cases of autism has
not been ruled out.31
Neuropsychological correlates of ASD include
impairments in executive functioning (e.g., simulta-
neously engaging in multiple tasks),32 weak central
coherence (integrating information into meaningful
wholes),33 and deﬁcits in theory-of-mind tasks
(taking the perspective of another person).34
Familial Pattern and Genetic Factors
The high recurrence risk for autism in siblings
and even higher concordance for autism in
identical twins has provided strong support for
the importance of genetic factors.30 Higher rates
of autism are consistently noted in siblings of
affected children. Recurrence risk has typically
been cited at 2% to 10%, but a recent prospective
longitudinal study has reported a rate of 18.7%
when the broad autism spectrum is considered.35
Identiﬁed risk factors for ASD appear to include
closer spacing of pregnancies, advanced maternal
or paternal age, and extremely premature birth
(<26 weeks’ gestational age).36-38 In addition,
high rates of learning/language problems and
social disability and a possible increase in the risk
for mood and anxiety disorders has been noted in
family members.
It is now clear that multiple genes are involved
in autism.30,39 Over the past several years, studies
have supported a role for common (present in>5%
of the general population) and rare genetic varia-
tions contributing to autism.40 The rate of progress
in gene discovery has been increasing rapidly over
the past several years and these results are already
beginning to inﬂuence clinical practice with regard
to genetic testing, as noted below.41DIFFERENTIAL DIAGNOSIS
ASD must be differentiated from speciﬁc develop-
mental disorders (including language disorders),AL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
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attachment disorder, obsessive-compulsive dis-
order, intellectual disability, anxiety disorders
including selective mutism, childhood-onset
schizophrenia, and other organic conditions.
A diagnosis of autism is made when the
requisite DSM-5 symptoms are present and other
disorders have been adequately ruled out. In
autism it is typical for parents to report that
there was no period of normal development or
that there was a history of unusual behaviors
(e.g., the child seemed too good and undemand-
ing as an infant). Less commonly, a period of
apparently normal development is reported before
a regression (loss of skills). The topic of regression
in autism remains an active area of current inves-
tigation. Developmental regression is typical in
Rett syndrome but also can be observed in
other conditions (e.g., childhood-onset schizo-
phrenia or degenerative CNS disorders).
Developmental language disorders have an
impact on socialization and may be mistaken for
an ASD. The distinction is particularly difﬁcult in
preschool children. However, 2 behaviors have
been reported to consistently differentiate autistic
children from language-impaired peers at 20 and
42 months of age, namely pointing for interest
and use of conventional gestures.42 Similarly,
differentiating mild to moderate developmental
delay from ASD may be difﬁcult, particularly
when evaluating the younger child (see Chawarska
and Volkmar42 for a detailed discussion). One
study identiﬁed some items on the Autism Diag-
nostic Interview that differentiated between these
2 groups at 24 months, especially directing atten-
tion (showing) and attention to voice (Table 1).43-56
At 36 months, 4 items correctly classiﬁed all
subjects: use of other’s body, attention to voice,
pointing, and ﬁnger mannerisms. From 38 to 61
months, children with autism were more likely
to show impaired nonverbal behaviors (such as
eye contact) to regulate social interaction. In
childhood, there may be diagnostic overlap be-
tween ASD and attention-deﬁcit/hyperactivity
disorder, making the differential diagnosis
difﬁcult.57,58
Children with reactive attachment disorder
may exhibit deﬁcits in attachment and therefore
inappropriate social responsivity, but these usu-
ally improve substantially if adequate caretaking
is provided. Obsessive-compulsive disorder has a
later onset than ASD, is not typically associated
with social and communicative impairments, and
is characterized by repetitive patterns of behaviorJOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATR
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anxiety disorders, such as excessive worry, the
need for reassurance, the inability to relax, and
feelings of self-consciousness, are also seen in
ASD, particularly in higher functioning in-
dividuals. However, the 2 conditions can be
differentiated by the prominent social and
communicative impairments seen in ASD but not
anxiety disorders, and the developed social insight
of children with anxiety disorders, which is not
seen in ASD. Differentiating childhood schizo-
phrenia from autism can be difﬁcult, because they
are characterized by social impairments and odd
patterns of thinking. However, ﬂorid delusions
and hallucinations are rarely seen in autism.COMORBIDITIES
Given difﬁculties in communication (e.g., mutism)
and cognitive impairment, issues of comorbidity
in ASD can be quite complex. The process of
diagnostic overshadowing (the tendency to fail
to diagnose other comorbid conditions when
a more noticeable condition is present) may
occur.59 Attempts to determine comorbidity
prevalence in ASD have been hampered by
methodologic issues, although most studies have
shown increased rates of anxiety and attentional
disorders.60
In most epidemiologically based samples of
persons with autistic disorder, approximately
50% exhibit severe or profound intellectual
disability, 35% exhibit mild to moderate intellec-
tual disability, and the remaining 20% have
IQs in the normal range.18 For children with
autistic disorder, verbal skills are typically more
impaired than nonverbal skills. For children with
Asperger’s disorder, the reverse pattern is some-
times observed and the proﬁle of nonverbal
learning disability may be present.61 Clearly, in-
tellectual impairment is not an essential diag-
nostic feature of autism, and thus it is necessary
and important for the diagnosis of intellectual
disability to be made.
A range of behavioral difﬁculties can be
observed in ASD, including hyperactivity,
obsessive-compulsive phenomena, self-injury,
aggression, stereotypies, tics, and affective
symptoms. The issue of whether these qualify as
additional disorders is complex.3 Affective
symptoms are frequently observed and include
lability, inappropriate affective responses, anxi-
ety, and depression. Impairments in emotion
regulation processes can lead to under- andY
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TABLE 1 Summary of Selected Assessment Instruments for Autism Spectrum Disordera
Scale (see legend) Uses Age Range Method of Administration Population Studied Scale characteristics Reference
ABC screening children parent rated AD 57 items, scale 1-4 Krug et al., 198043
CARS screening children clinician rated AD 15 items, scale 1-4 Schopler et al., 198044
M-CHAT screening toddlers parent rated AD 23 items, yes/no Robins et al., 200145
CSBS-DP-IT-Checklist screening toddlers parent rated AD 24 items Wetherby et al., 200846
ASQ screening child/adult parent rated AD/AspD 40 items, yes/no Berument et al., 199947
AQ screening child/adult self or parent rated AspD 50 items, scale 0-3 Baron-Cohen et al., 200148
CAST screening 4-11 years parent rated AspD 37 items, yes/no Scott et al., 200249
ASDS screening 5-18 years parent or teacher rated AspD 50 items, yes/no Myles et al., 200050
GADS screening 3-22 years parent or teacher rated AspD 32 items, scale 0-3 Gilliam, 200151
ASDI screening child/adult interview þ clinician rated AspD 50 items, yes/no Gillberg et al., 200152
SRS screening 4-18 years parent or teacher rated AspD 65 items, scale 1-4 Constantino et al., 200353
ADI diagnostic child/adult interview þ clinician rated AD/AspD see text Lord et al., 200354
DISCO diagnostic child/adult interview þ clinician rated AD/AspD see text Wing et al., 200255
ADOS diagnostic child/adult semi-structured interactive session AD/AspD see text Lord et al., 199456
Note: ABC ¼ Autism Behavior Checklist; AD ¼ autism disorder; ADI ¼ Autism Diagnostic IntervieweRevised; ADOS ¼ Autism Diagnostic Observation Schedule; AQ ¼ Autism Quotient; ASDI ¼ Asperger Syndrome
Diagnostic Interview; ASDS ¼ Asperger Syndrome Diagnostic Scale; AspD ¼ Asperger’s disorder; ASQ ¼ Autism Screening Questionnaire; CARS ¼ Childhood Autism Rating Scale; CAST ¼ Childhood Autism
Screening Test; M-CHAT ¼ Checklist for Autism in Toddlers; CSBS-DP-IT-Checklist ¼ Communication and Symbolic Behavior Scales Developmental Profile Infant-Toddler Checklist; DISCO ¼ Diagnostic Interview for Social
and Communication Disorders; GADS ¼ Gilliam Asperger’s Disorder Scale; Parent ¼ primary caregiver; SRS ¼ Social Responsiveness Scales.
aNote that these instruments may need to be revised to provide evidence of validity for DSM-5 ASD and supplement but DO NOT REPLACE clinical diagnosis.
JO
U
RN
A
L
O
F
TH
E
A
M
ERIC
A
N
A
C
A
D
EM
Y
O
F
C
H
ILD
&
A
D
O
LESC
EN
T
P
SYC
H
IA
TRY
2
4
2
w
w
w
.jaacap.org
VO
LU
M
E
53
N
U
M
BER
2
FEBRU
A
RY
2014
A
A
C
A
P
O
FFIC
IA
L
A
C
TIO
N
AACAP OFFICIAL ACTIONover-reactivity.62 Overt clinical depression is some-
times observed and this may be particularly true
for adolescents with Asperger’s disorder.15 Case
reports and case series have suggested possible
associations with bipolar disorders and tics and
Tourette’s syndrome. Bullying involvement,
including victimization and perpetration, occurs
more frequently in general educational settings.63
Attentional difﬁculties also are frequent in
autism, reﬂecting cognitive, language, and social
problems.64 The historical prohibition on making
an additional diagnosis of attention-deﬁcit/
hyperactivity disorder in those with ASD has
been removed in the DSM-5. Notably, a subset of
children with ASD with elevated scores for hy-
peractivity showed a 49% response rate in a large
randomized controlled trial of methylphenidate
treatment.64EVIDENCE BASE FOR PRACTICE
PARAMETERS
In this Parameter, recommendations for best
assessment and treatment practices are stated in
accordance with the strength of the underlying
empirical and/or clinical support.
 Clinical standard [CS] is applied to recom-
mendations that are based on rigorous empir-
ical evidence (e.g., meta-analyses, systematic
reviews, individual randomized controlled tri-
als) and/or overwhelming clinical consensus.
 Clinical guideline [CG] is applied to recom-
mendations that are based on strong empirical
evidence (e.g., nonrandomized controlled trials,
cohort studies, case-control studies) and/or
strong clinical consensus.
 Clinical option [OP] is applied to recommen-
dations that are based on emerging empirical
evidence (e.g., uncontrolled trials or case se-
ries/reports) or clinical opinion but lack strong
empirical evidence and/or strong clinical
consensus.
 Not endorsed [NE] is applied to practices that
are known to be ineffective or contraindicated.
The strength of the empirical evidence is rated
in descending order as follows:
 [rct] Randomized controlled trial is applied to
studies in which subjects are randomly
assigned to at least 2 treatment conditions.
 [ct] Controlled trial is applied to studies in
which subjects are nonrandomly assigned to at
least 2 treatment conditions.JOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATR
VOLUME 53 NUMBER 2 FEBRUARY 2014 [ut] Uncontrolled trial is applied to studies in
which subjects are assigned to 1 treatment
condition.
 [cs] Case series/report is applied to a case
series or a case report.ASSESSMENT
Recommendation 1. The developmental assess-
ment of young children and the psychiatric
assessmentofall childrenshould routinely include
questions about ASD symptomatology [CS].
Screening should include inquiries about the
core symptomsofASD, including social relatedness
and repetitive or unusual behaviors. Screening
instruments have been developed that may be
helpful to the clinician. Some of these instruments
are completed by clinicians and others by primary
caregivers (Table 1).43-56 Screening is applicable
to young children and to infants, when the diag-
nosis may ﬁrst be considered. In some instances,
screening may be relevant to older children,
e.g., those who are more intellectually able and
whose social disability is therefore more likely to
be detected later.
Recommendation 2. If the screening indicates
signiﬁcant ASD symptomatology, a thorough
diagnostic evaluation should be performed to
determine the presence of ASD [CS].
Currently, biological diagnostic markers are
not available and diagnosis rests on careful
examination of the child. A standard psychiat-
ric assessment should be followed,65 including
interviews with the child and family and a re-
view of past records and historical information.
The history and examination should be con-
ducted with careful consideration of DSM-5
diagnostic criteria. Although the DSM-5 criteria
are intended to be independent of age and
intellect, the diagnosis of autism in infants and
very young children is more challenging, and
some features (e.g., stereotyped movements)
may develop later.5 Systematic attention to
the areas relevant to differential diagnosis
is essential. Information on the nature of changes
over the course of development, e.g., in re-
sponse to intervention, is helpful. The history
should include a review of past and current
educational and behavioral interventions and
information regarding family history and rele-
vant psychosocial issues. Consideration of
possible comorbid diagnoses is an important
focus of assessment.Y
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broad areas of social interaction and restricted,
repetitive behaviors. The child’s age and devel-
opmental level may dictate some modiﬁcation in
assessment procedures. Clinicians should be
sensitive to ethnic, cultural, or socioeconomic
factors that may affect assessment.
Various instruments for the assessment of ASD
have been developed (Table 143-56, see Coonrod
and Stone66 for a review). As a practical matter,
all these instruments vary in their usefulness for
usual clinical practice. Some require speciﬁc
training. The use of such instruments supple-
ments, but does not replace, informed clinical
judgment.3
Recommendation 3. Clinicians should coordi-
nate an appropriate multidisciplinary assess-
ment of children with ASD [CS].
All children with ASD should have a medical
assessment, which typically includes physical ex-
amination, a hearing screen, a Wood’s lamp ex-
amination for signs of tuberous sclerosis, and
genetic testing, which may include G-banded
karyotype, fragile X testing, or chromosomal
microarray. In a community sample of children
with ASD, diagnostic yields were 2.5% for karyo-
type testing, 0.57% for fragile X testing, and 24%
for chromosomal microarray.67 Chromosomal
microarray has been recommended by medical
geneticists as the standard of care for the initial
evaluation of children with developmental dis-
abilities and/or ASDs.68 These tests currently
detect known abnormalities clearly associated
with increased rates of ASD (e.g., 15q11-13
maternal duplications and duplications and de-
letions of chromosome 16p11.2) and genetic vari-
ations of uncertain signiﬁcance. Recent data from a
study of families with only a single affected child
have shown that lower IQ is not a strong predictor
of a positive chromosomal ﬁnding.69 Any
abnormal or indeterminate result from such a
study warrants referral for further genetic evalu-
ation and counseling. The yield of genetic testing
in the presence of clinical suspicion is currently in
the range of at least one third of cases.70
Unusual features in the child (e.g., history of
regression, dysmorphology, staring spells, family
history) should prompt additional evaluations.
The list of potential organic etiologies is large but
falls into the categories of infectious (e.g.,
encephalitis or meningitis), endocrinologic (e.g.,
hypothyroidism), metabolic (e.g., homocystinuria),
traumatic (e.g., head injury), toxic (e.g., fetalJOURN
244 www.jaacap.orgalcohol syndrome),4 or genetic (e.g., chromosomal
abnormality). Certain developmental disorders,
most notably Landau-Kleffner syndrome, also
should be ruled out. In this condition, a highly
distinctive EEG abnormality is present and asso-
ciated with development of a marked aphasia.71
Genetic or neurologic consultation, neuroimaging,
EEG, and additional laboratory tests should be
obtained when relevant, based on examination or
history (e.g., testing for theMeCP2 gene in cases of
possible Rett’s disorder).72
Psychological assessment, including measure-
ments of cognitive ability and adaptive skills, is
indicated for treatment planning and helps to
frame observed social-communication difﬁculties
relative to overall development. The results of
standard tests of intelligence may show consid-
erable scatter. Unusual islets of ability (“splinter
skills”) may be present. For children with autism,
these sometimes take the form of unusual ability
(“savant skills”), e.g., the ability to produce
intricate drawings or engage in calendar calcula-
tions. For higher functioning children, areas of
special interest are often present and the single-
minded pursuit of these interests may interfere
with the child’s ability to learn. Psychological
tests clarify areas of strength and weakness
useful in designing intervention programs and
may need to include instruments valid for a
nonverbal population.7
Communication assessment, including mea-
surements of receptive and expressive vocabulary
and language use (particularly social or prag-
matic), is helpful for diagnosis and treatment
planning.73 Occupational and physical therapy
evaluations may be needed to evaluate sensory
and/or motor difﬁculties.74 Sleep is an important
variable to assess in individuals with ASD.75
When members of multiple disciplines are in-
volved in assessment, it is optimal that coordina-
tion occur among the various professionals.TREATMENT
Recommendation 4. The clinician should help
the family obtain appropriate, evidence-based,
and structured educational and behavioral in-
terventions for children with ASD [CS].
Structured educational and behavioral in-
terventions have been shown to be effective for
many children with ASD76 and are associated
with better outcome.8 As summarized in the
National Research Council report,76 the quality
of the research literature in this area is variable,AL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
VOLUME 53 NUMBER 2 FEBRUARY 2014
AACAP OFFICIAL ACTIONwith most studies using group controls or single-
subject experimental methods. In general, stud-
ies using more rigorous randomized group com-
parisons are sparse, reﬂecting difﬁculties in
random assignment and control comparisons.
Other problems include lack of attention to sub-
ject characterization, generalization of treatment
effects, and ﬁdelity of treatment implementation.
Despite these problems, various comprehensive
treatments approaches have been shown to have
efﬁcacy for groups of children, although none of
the comprehensive treatment models has clearly
emerged as superior.76
Behavioral
Behavioral interventions such as Applied Behav-
ioral Analysis (ABA) are informed by basic and
empirically supported learning principles.77 A
widely disseminated comprehensive ABA pro-
gram is Early Intensive Behavioral Intervention
for young children, based on the work of Lovaas
et al.78 Early Intensive Behavioral Intervention is
intensive and highly individualized, with up to
40 hours per week of one-to-one direct teaching,
initially using discrete trials to teach simple skills
and progressing to more complex skills such as
initiating verbal behavior. A meta-analysis found
Early Intensive Behavioral Intervention effective
for young children but stressed the need for
more rigorous research to extend the ﬁndings.79
Behavioral techniques are particularly useful
when maladaptive behaviors interfere with the
provision of a comprehensive intervention pro-
gram. In such situations, a functional analysis of
the target behavior is performed, in which pat-
terns of reinforcement are identiﬁed and then
various behavioral techniques are used to pro-
mote a desired behavioral alternative. ABA
techniques have been repeatedly shown to have
efﬁcacy for speciﬁc problem behaviors,80 and
ABA has been found to be effective as applied to
academic tasks,81[ut] adaptive living skills,82[ut]
communication,83[ut] social skills,84[ut] and voca-
tional skills.85[ct] Because most children with ASD
tend to learn tasks in isolation, an explicit focus
on generalization is important.86
Communication
Communication is a major focus of intervention
and typically will be addressed in the child’s
individualized educational plan in coordination
with the speech-language pathologist. Children
who do not yet use words can be helped through
the use of alternative communication modalities,JOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATR
VOLUME 53 NUMBER 2 FEBRUARY 2014such as sign language, communication boards,
visual supports, picture exchange, and other
forms of augmentative communication. There is
some evidence for the efﬁcacy of the Picture
Exchange Communication System, sign language,
activity schedules, and voice output communica-
tion aids.87[rct],88-90 For individuals with ﬂuent
speech, the focus should be on pragmatic language
skills training. Children and adolescents with
ﬂuent speech may, for example, be highly verbal
but have severely impaired pragmatic language
skills that can be addressed through explicit
teaching. Many programs to enhance social
reciprocity and pragmatic language skills are
currently available (Table 2; see Reichow and
Volkmar91 for an extensive review).92-103
Educational
There is consensus that children with ASD need a
structured educational approach with explicit
teaching.76 Programs shown to be effective typi-
cally involve planned, intensive, individualized
intervention with an experienced, interdisci-
plinary team of providers, and family involve-
ment to ensure generalization of skills. The
educational plan should reﬂect an accurate
assessment of the child’s strengths and vulnera-
bilities, with an explicit description of services to
be provided, goals and objectives, and pro-
cedures for monitoring effectiveness. Although
the curricula used vary across programs, they
often share goals of enhancing verbal and
nonverbal communication, academic skills, and
social, motor, and behavioral capabilities. In
some instances, particularly for younger children,
a parent-education and home component may be
important. Development of an appropriate indi-
vidualized educational plan is central in
providing effective service to the child and fam-
ily. Efﬁcacy has been shown for 2 of the struc-
tured educational models, the Early Start Denver
Model104[rct] and the Treatment and Education of
Autism and related Communication handi-
capped Children program,105[ct] but signiﬁcant
challenges remain in disseminating knowledge
about effective interventions to educators.
Other Interventions
There is a lack of evidence for most other forms
of psychosocial intervention, although cognitive
behavioral therapy has shown efﬁcacy for anxiety
and anger management in high functioning youth
with ASD.106[rct],107[rct] Studies of sensory ori-
ented interventions, such as auditory integrationY
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TABLE 2 Methods Available for the Delivery of Social Reciprocity/Pragmatic Language-Oriented Interventions
Developmental
Level Method Notes Reference
Infant/preschool
(play based)
guided participation adult coaching and mediation by
trained peers
Schuler and Wolfberg,
200292
Do-Watch-Listen-Say careful selection of play materials to
foster participation; organization
of environment to facilitate
participation and cooperation
Quill, 200093
play organizers neurotypical peers taught to
encourage sharing, helping, and
praising to facilitate play; some
evidence of generalization
Strain et al., 197794
buddy skills teaches neurotypical peers to stay
with, play with, and talk to their
“buddies”; some evidence of
improvement in the frequency of
social communication that was
generalized to other interactions
Goldstein and Wikstrom,
199695
School age social stories state a problem and give the child
an acceptable response to it;
usually focuses on maladaptive
behaviors; little evidence of
generalization and maintenance
Gray, 200096
social skills groups see text Kamps et al., 199797
peer network/circle of
friends
typical peers taught to initiate and
model appropriate social
interactions; results have shown
improvement in interaction and
generalization to new settings
Kamps et al., 199797;
Whitaker et al., 199898
Adolescence peer network/circle of
friends
see above Whitaker et al., 199898;
Paul, 200399
visual schedule/verbal
rehearsal
using written and pictorial
representations of expected
activities and behavior
Klin and Volkmar, 2000100;
Hodgdon, 1995101
social skills group see text Paul, 200399
social thinking addresses underlying social
cognitive knowledge required for
expression of related social skills;
promotes teaching the “why”
behind socialization
Crooke et al., 2007102
training scripts scripts are provided that give the
opportunity to ask questions in
response to others ¼ initiation of
conversation
Klin and Volkmar, 2000103
AACAP OFFICIAL ACTIONtraining, sensory integration therapy, and touch
therapy/massage, have contained methodo-
logic ﬂaws and have yet to show replicable
improvements.108,109 There is also limited evi-
dence thus far for what are usually termed
developmental, social-pragmatic models of in-
tervention, such as Developmental-Individual
Difference-Relationship Based/Floortime, Re-
lationship Development Intervention, SocialJOURN
246 www.jaacap.orgCommunication Emotional Regulation and
Transactional Support, and Play and Language
for Autistic Youths, which generally use natu-
ralistic techniques in the child’s community
setting to develop social communication abili-
ties. Children with ASD are psychiatrically
hospitalized at substantially higher rates than
the non-ASD child population.110 The efﬁcacy
of this intervention is unknown, although thereAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
VOLUME 53 NUMBER 2 FEBRUARY 2014
TABLE 3 Randomized Controlled Trials of Psychotropic Medications in Children and Adolescents With Autism Spectrum Disorder (ASD)
Agent Study Target Symptoms Dose Demographics Signiﬁcant Side Effects Primary Outcome(s)
a2 Agonists
Clonidine Jaselskis et al.,
1992116
hyperactivity, irritability,
inappropriate speech,
stereotypy
0.15-0.20 mg
divided 3/d
8 children 5-13 y old hypotension, drowsiness statistically and clinically
relevant decrease in ABC
Irritability subscale
Guanfacine Handen et al.,
2008117
hyperactivity, inattention 1-3 mg divided
3/d
7 children with ASD
5-9 y old
drowsiness, irritability 45% with >50% decrease in
ABC Hyperactivity subscale
Antipsychotics
Aripiprazole bMarcus et al.,
2009118
irritability, hyperactivity,
stereotypy, social
withdrawal, inappropriate
speech
5, 10, or 15 mg/d
ﬁxed dose
218 children 6-17 y old somnolence, weight
gain, drooling, tremor,
fatigue, vomiting
56% positive responsea for
aripiprazole 5 mg vs. 35%
on placebo; signiﬁcant
improvement in Irritability,
Hyperactivity, and
Stereotypy subscales
bOwen et al.,
2009119
irritability, hyperactivity,
stereotypy, social
withdrawal inappropriate
speech
5-15 mg/d
ﬂexibly dosed
98 children 6-17 y old somnolence, weight
gain, drooling, tremor,
fatigue, vomiting
52% positive responsea for
aripiprazole vs. 14% on
placebo; signiﬁcant
improvement in Irritability,
Hyperactivity, and
Stereotypy subscales
Haloperidol Anderson et al.,
1984120
multiple behavioral
symptoms, global
functioning
0.5-4 mg/d 40 children 2-7 y old sedation, irritability,
extrapyramidal
symptoms (>25%)
behavioral symptoms
improved with signiﬁcant
decrease in 8 of 14 items
of CPRS
Anderson et al.,
1989121
multiple behavioral
symptoms, global
functioning
0.25-4 mg/d 45 children 2-7 y old sedation,
extrapyramidal
symptoms
behavioral symptoms
improved with signiﬁcant
decrease in 7 of 14 items
of CPRS
Olanzapine bHollander et al.,
2006122
global functioning,
aggression, compulsions,
irritability
7.5-12.5 mg/d 11 children 6-14 y old weight gain, sedation 50% of those on olanzapine
much or very much
improved in global
functioning vs. 20% on
placebo
Risperidone RUPP, 2002123 irritability, hyperactivity,
stereotypy, social
withdrawal, inappropriate
speech
0.5-3.5 mg/d 101 children 5-17 y old weight gain, increased
appetite, fatigue,
drowsiness, drooling,
dizziness
69% had positive responsea
on risperidone vs. 12%
positive responsea on
placebo; signiﬁcant positive
ﬁndings for hyperactivity
and stereotypy
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TABLE 3 Continued
Agent Study Target Symptoms Dose Demographics Signiﬁcant Side Effects Primary Outcome(s)
bShea et al.,
2004124
irritability, hyperactivity,
stereotypy, social
withdrawal, inappropriate
speech
0.02-0.06 mg/kg/d 79 children 5-12 y old weight gain,
somnolence,
64% improvement in ABC
Irritability subscale on
risperidone vs. 31%
improvement on placebo;
signiﬁcant positive ﬁnding
for hyperactivity
McDougle et al.,
2005125
social and communication
impairment, repetitive
behavior and stereotypy
0.5-3.5 mg/d 101 children 5-17 y old weight gain, increased
appetite, fatigue,
drowsiness, drooling,
dizziness
signiﬁcant responsec for
repetitive behavior and
stereotypy on risperidone
Risperidone vs.
haloperidol
bMiral et al.,
2008126
behavior, social, sensory,
language
0.01-0.08 mg/kg/d 30 children 8-18 y old EPS, weight gain,
gynecomastia
risperidone reported superior
to haloperidol only on ABC
total score, no subscales
reported
Mood stabilizers
Valproic acid Hellings et al.,
2005127
irritability 20 mg/kg/d,
average level
75-78
30 subjects 6-20 y old increased appetite,
skin rash
no signiﬁcant difference for
ABC Irritability subscale
bHollander et al.,
2005128
repetitive behavior 500-1,500 mg/d 12 children 5-17 y old,
1 adult 40 y old
irritability, aggression statistically signiﬁcant
decrease in repetitive
behavior on CY-BOCS
Hollander et al.,
2010129
global irritability dosed to mean level
of 89.8 mg/mL
27 children 5-17 y old skin rash, irritability 62.5% positive response for
irritability on CGI on
divalproex vs. 9.09% on
placebo
Lamotrigine bBelsito et al.,
2001130
irritability, social behavior 5 mg/kg/d 28 children 3-11 y old insomnia, hyperactivity no signiﬁcant difference in
irritability or social behavior
on multiple instruments
Levetiracetam bWasserman et al.,
2006131
irritability, global
functioning
20-30 mg/kg/d 20 children 5-17 y old aggression no signiﬁcant difference in
global functioning or
irritability
Norepinephrine
reuptake
inhibitors
Atomoxetine HCI bHarfterkamp et al.,
2012132
hyperactivity, inattention 1.2 mg/kg/d 97 children 6-17 y old nausea, anorexia,
fatigue, early
wakening
signiﬁcant difference in the
ADHD-RS for active
treatment group; no
difference in CGI-I
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TABLE 3 Continued
Agent Study Target Symptoms Dose Demographics Signiﬁcant Side Effects Primary Outcome(s)
bArnold et al.,
2006133
hyperactivity, inattention 20-100 mg divided
2, mean 44
mg/d
16 children 5-15 y old upper GI symptoms,
fatigue, racing heart
57% positive responsea for
parent-rated ABC
Hyperactivity subscale vs.
25% on placebo
Serotonin reuptake
inhibitors
Citalopram King et al., 2009134 repetitive behavior 2.5-20 mg/d, mean
16 mg/d
149 children 5-17 y old hyperactivity, insomnia,
inattention, impulsivity,
diarrhea, stereotypy
no signiﬁcant difference in
repetitive behavior on CGI-I
and CY-BOCS PDD
Fluoxetine Hollander et al.,
2005135
repetitive behavior 2.4-20 mg/d, mean
9.9 mg/d
39 children 5-17 y old none signiﬁcant statistically signiﬁcant
decrease in repetitive
behavior on CY-BOCS
Compulsions scale
Clomipramine Gordon et al.,
1993136
stereotypy, repetitive
behavior, compulsions
25-250 mg/d, mean
152 mg/d
12 children 6-18 y old insomnia, constipation,
twitching, tremors
decrease in repetitive
behavior on CPRS
Remington et al.,
2001137
stereotypy, irritability,
hyperactivity
100-150 mg/d,
mean 128.4 mg/d
31 subjects <20 y old lethargy, tremors,
tachycardia, insomnia,
diaphoresis, nausea
no signiﬁcant difference in
stereotypy, irritability, or
hyperactivity for
clomipramine on ABC
Stimulants
Methylphenidate RUPP, 2005138 hyperactivity 7.5-50 mg/d
divided 3/d
58 children 5-14 y old decreased appetite,
insomnia, irritability,
emotionality
49% positive respondersa for
hyperactivity vs. 15.5% on
placebo
Pearson et al.,
2013139
hyperactivity, inattention 10-40 mg
each morning,
methylphenidate
extended release
24 children 7-12 y old decreased appetite,
insomnia
signiﬁcant decrease in
hyperactivity and inattention
on multiple teacher and
parent measurements
Handen et al.,
2000140
hyperactivity 0.3-0.6 mg/kg/
dose, 2-3/d
13 children 5-11 y old social withdrawal,
irritability
8 of 13 children with >50%
decrease in hyperactivity on
Teacher Conners
Hyperactivity subscale
Quintana et al.,
1995141
hyperactivity 10-20 mg 2/d 10 children 7-11 y old irritability, anorexia,
insomnia
decrease in ABC
Hyperactivity subscale by 8
points over placebo
Miscellaneous
Amantadine bKing et al.,
2001142
hyperactivity, irritability 2.5-5.0 mg/kg/d 39 children 5-19 y old insomnia no statistical difference in
parent ABC Hyperactivity or
Irritability subscales,
statistical improvement in
clinician Hyperactivity and
Inappropriate Speech
subscales
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TABLE 3 Continued
Agent Study Target Symptoms Dose Demographics Signiﬁcant Side Effects Primary Outcome(s)
Cyproheptadine
(in combination
with haloperidol)
Akhondzadeh et al.,
2004143
ABC total score, CARS Titrated up to 0.2
mg/kg/d
40 children 3-11 y old none signiﬁcant, trend
toward increased
appetite
statistically signiﬁcant
difference in ABC total score
and CARS diagnostic
screening tool, with
unknown clinical
signiﬁcance
Donepezil Chez et al., 2003144 “autistic behavior,”
expressive-receptive
communication
1.25-2.5 mg/d 43 children 2-10 y old diarrhea, stomach
cramping, irritability
“autistic behavior”
statistically, improved on
CARS diagnostic screening
tool with unknown clinical
signiﬁcance
Naltrexone Willemsen-Swinkels
et al., 1995145
“social behavior,” irritability single 40-mg dose 20 children 3-7 y old sedation, increased
stereotypy
no effect on social behavior;
signiﬁcant decrease on ABC
Irritability subscale vs.
placebo
bKolmen et al.,
1995146
hyperactivity,
communication initiation
1 mg/kg/d 13 children 3-8 y old transient sedation no signiﬁcant difference in
communication initiation
bFeldman et al.,
1999147
communication 1 mg/kg/d 24 children, 3-8 y old transient sedation no signiﬁcant difference in
multiple communication
measurements
Campbell et al.,
1993148
CGI, CPRS, discriminant
learning, hyperactivity
0.5-1 mg/kg/d 18 children 3-8 y old increased aggression
and stereotypy
no signiﬁcant difference on
CGI or CPRS or discriminant
learning; positive trend for
hyperactivity
Campbell et al.,
1990149
hyperactivity, discriminant
learning, self-injurious
behavior
0.5-1 mg/kg/d 41 children 3-8 y old none signiﬁcant signiﬁcantly decreased
hyperactivity; no effect on
discriminant learning;
positive trend for self-
injurious behavior
Pentoxifylline (in
combination with
risperidone)
Akhondzadeh et al.,
2010150
irritability, hyperactivity,
stereotypy, social
withdrawal, inappropriate
speech
200-600 mg/d 40 children 4-12 y old sedation, GI effects,
increased appetite
signiﬁcant improvement on
ABC Irritability and Social
Withdrawal subscales
Note: ABC ¼ Autism Behavior Checklist; ADHD-RS ¼ Attention-Deficit/Hyperactivity Disorder Rating Scale; CY-BOCS ¼ Children’s Yale-Brown Obsessive Compulsive Scale; CARS ¼ Childhood Autism Rating Scale;
CPRS ¼ Children’s Psychiatric Rating Scale; EPS ¼ extrapyramidal side effects; GI ¼ gastrointestinal; PDD ¼ pervasive developmental disorder; RUPP ¼ Research Units on Pediatric Psychopharmacology.
aA positive response in this study was defined as a >25% reduction in the ABC subscale and a Much Improved or Very Much Improved rating on the Clinical Global Impression–Global Improvement (CGH).
bStudy identified as funded by pharmaceutical industry.
cA positive response in this study was defined as a greater than 25% decrease in ABC (CY-BOCS) compulsions score and a much improved or very much improved rating on the CGI-I.
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AACAP OFFICIAL ACTIONis preliminary evidence for the efﬁcacy of
hospital psychiatry units that specialize in the
population.111
Recommendation 5. Pharmacotherapy may be
offered to children with ASD when there is a
speciﬁc target symptom or comorbid condi-
tion [CG].
Pharmacologic interventions may increase the
ability of persons with ASD to proﬁt from
educational and other interventions and to
remain in less restrictive environments through
the management of severe and challenging
behaviors. Frequent targets for pharmacologic
intervention include associated comorbid condi-
tions (e.g., anxiety, depression) and other fea-
tures, such as aggression, self-injurious behavior,
hyperactivity, inattention, compulsive-like be-
haviors, repetitive or stereotypic behaviors, and
sleep disturbances. As with other children and
adolescents, various considerations should inform
pharmacologic treatment.112 Risperidone113[rct]
and aripiprazole114[rct] have been approved byTABLE 4 Resources for Parents
ASPEN TM, Inc. (Asperger Syndrome Education
Network) (http://www.aspennj.org)
A
Autism Society of America (http://www.autism-
society.org)
T
Autism Speaks (http://www.autismspeaks.org) A
Division TEACCH (Treatment and Education of
Autism and related Communication handicapped
Children, University of North Carolina at Chapel
Hill) (www.teacch.com)
T
LDAA (Learning Disabilities Association of America)
(http://www.ldanatl.org)
T
OASIS (Online Asperger Syndrome Information and
Support) (http://www.asperger.org)
G
Yale Child Study Center (www.autism.fm) In
JOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATR
VOLUME 53 NUMBER 2 FEBRUARY 2014the Food and Drug Administration for the
treatment of irritability, consisting primarily
of physical aggression and severe tantrum
behavior, associated with autism. There is a
growing body of controlled evidence for phar-
macologic intervention,115 and a summary of
randomized controlled trials of medication in
children with ASD is included (Table 3).116-150
Combining medication with parent training is
moderately more efﬁcacious than medication
alone for decreasing serious behavioral distur-
bance and modestly more efﬁcacious for adap-
tive functioning.151[rct],152[rct] Individuals with
ASD may be nonverbal, so treatment response is
often judged by caregiver report and observa-
tion of speciﬁc behaviors. Although this may
help document the effectiveness of the selected
medication, one must remember that an overall
goal of treatment is to facilitate the child’s
adjustment and engagement with educational
intervention. Several objective rating scales
also are available to help monitor treatment
response.153regional nonproﬁt organization providing families and those
individuals affected with Asperger syndrome and related
disorders with information, support, and advocacy.
he mission of the Autism Society of America is to promote
lifelong access and opportunities for persons within the autism
spectrum and their families to be fully included, participating
members of their communities through advocacy, public
awareness, education, and research related to autism.
utism Speaks is an autism science and advocacy organization
dedicated to funding research into the causes, prevention,
treatments, and a cure for autism; increasing awareness of
autism spectrum disorders; and advocating for the needs of
individuals with autism and their families.
he TEACCH Web site includes information about their
program, educational and communication approaches to
teaching individuals with autism, their research and training
opportunities, and information and resources on autism.
he LDAA site includes information and resources on many
learning disabilities, including learning disabilities involving a
signiﬁcant social component, such as autism and Asperger
syndrome.
eneral information on Asperger syndrome and related
disorders, including resources and materials, announcements
of major pertinent events and publications, and being the
major “intersection” for communication among parents,
clinicians, educators, and individuals with social disabilities.
formation on autism, Asperger syndrome, and related
disorders, lists of resources organized by state, and parent
support organizations and advocacy agencies.
Y
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AACAP OFFICIAL ACTIONRecommendation 6. The clinician should
maintain an active role in long-term treatment
planning and family support and support of the
individual [CG].
Children’s and families’ need for help and sup-
port will change over time. The clinician should
develop a long-term collaboration with the family
and realize that service utilizationmaybe sporadic.
For very young children, issues of diagnosis and
identiﬁcation of treatment programs often will be
most important. For school-age children, psycho-
pharmacologic and behavioral issues typically
become more prominent. For adolescents, voca-
tional and prevocational training and thoughtful
planning for independence/self-sufﬁciency is
important. As part of this long-term engage-
ment, parents and siblings of children with ASD
will need support (Table 4). Although raising a
child with autism presents major challenges,
rates of parental separation and divorce are not
higher among parents of children with ASD than
those with non-ASD children.154
Recommendation 7. Clinicians should specif-
ically inquire about the use of alternative/com-
plementary treatments and be prepared to
discuss their risk and potential beneﬁts [CS].
Although most alternative or complementary
treatment approaches have very limited empirical
support for their use in children with ASD, they
are commonly pursued by families.155 It is
important that the clinician be able to discuss
these treatments with parents, recognizing the
motivation for parents to seek all possible treat-
ments. In most instances, these treatments have
little or no proved beneﬁt but also have little
risk.7 In a few instances, the treatment has been
repeatedly shown not to work (e.g., intravenous
infusion of secretin156 and oral vitamin B6 and
magnesium157[rct]), or randomized controlled
evidence does not support its use (e.g., the gluten-
free, casein-free diet,158 u-3 fatty acids,159 and
oral human immunoglobulin).160[rct] Some treat-
ments have greater potential risk to the child
directly (e.g., mortality and morbidity associated
with chelation161[cs]) or from side effects owing to
contaminants in “natural” compounds or indi-
rectly (e.g., by diverting ﬁnancial or psychosocial
resources). For a detailed review of alternative
treatments, see Jacobson et al.162 and Levy and
Hyman.163 Although more controlled studies of
these treatments are needed, it is important that
the family be able to voice their questions to
health care providers. Families may be guided toJOURN
252 www.jaacap.orgthe growing body of work on evidence-based
treatments in autism.164
PARAMETER LIMITATIONS
AACAP Practice Parameters are developed to
assist clinicians in psychiatric decision making.
These Parameters are not intended to deﬁne the
sole standard of care. As such, the Parameters
should not be deemed inclusive of all proper
methods of care or exclusive of other methods
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all of the circumstances presented by the patient
and his or her family, the diagnostic and treatment
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